The Pioneer platform is also not limited to comparing selective bacterial cytotoxic activities against human cancer versus immortalised non-transformed cells, but could potentially be used to compare any combination of cells that can be engineered to express the Colicin M and CAT proteins required and grow under these experimental conditions, including cells from other tissues or species. Here, CAT is linked to cancer.